Literature DB >> 23986433

Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center.

A Brooke Eastham1, Alisa N Femia2, Abrar Qureshi3, Ruth Ann Vleugels2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23986433     DOI: 10.1001/jamadermatol.2013.4773

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  6 in total

1.  Characterizing Disease Features and Other Medical Diagnoses in Patients With Pityriasis Rubra Pilaris.

Authors:  Katherine Halper; Benjamin Wright; Nolan J Maloney; Mindy M Kim; Vignesh Ravi; Scott Worswick; Donald K Lei
Journal:  JAMA Dermatol       Date:  2020-12-01       Impact factor: 10.282

2.  Ineffectiveness of tumor necrosis factor-α blockers and ustekinumab in a case of type IV pityriasis rubra pilaris.

Authors:  Vito Di Lernia; Elena Ficarelli; Magda Zanelli
Journal:  Indian Dermatol Online J       Date:  2015 May-Jun

3.  Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris.

Authors:  Mudit Chowdhary; Ulysses Davila; David J Cohen
Journal:  Case Rep Dermatol       Date:  2015-03-17

Review 4.  Management of refractory pityriasis rubra pilaris: challenges and solutions.

Authors:  Gaia Moretta; Erika V De Luca; Alessandro Di Stefani
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-11-09

5.  Serum ferritin levels and irregular use of iron chelators predict liver iron load in patients with major beta thalassemia: a cross-sectional study.

Authors:  Soheila Sobhani; Farzaneh Rahmani; Maryam Rahmani; Marzieh Askari; Farzad Kompani
Journal:  Croat Med J       Date:  2019-10-31       Impact factor: 1.351

6.  Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl.

Authors:  Lauren Bonomo; Aishwarya Raja; Kathryn Tan; Emma Guttman-Yassky
Journal:  JAAD Case Rep       Date:  2018-02-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.